Text Size

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

Gonzalez V.H., Berger B., Goldberg R., Gordon C.M., Khurana R.N., Angeles R., Shams N.

  • 2021
  • Translational vision science & technology
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Valley Retina Institute, TX, McAllen, United States; Retina Research Center, TX, Austin, United States; Bay Area Retina Associates, CA, United States; MI, Jackson, United States; Northern California Retina Vitreous Associates, Mountain View, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA; Santen USA, Emeryville, CA, USA; ProQR Therapeutics NV, MA, Cambridge, United States

Related Publications

Aging-associated changes of optical coherence tomography-measured ganglion cell-related retinal layer thickness and visual sensitivity in normal Japanese

Iwase A., Higashide T., Fujii M., Ohno Y., Tanaka Y., Kikawa T., Araie M.

Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study

Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D

Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial

Yoshida T.; Takagi Y.; Igarashi-Yokoi T.; Ohno-Matsui K.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022